We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
California Gov. Arnold Schwarzenegger has vetoed four bills that would have let state residents buy prescription drugs from Canada, as well as another bill that would have required pharmaceutical benefit managers (PBMs) to disclose the payments and discounts they receive from drugmakers.
Merck has announced a voluntarily withdrawal of its top-selling arthritis drug Vioxx after clinical studies found an increased risk of heart attack and stroke in patients taking the treatment.
A new business division created by Johnson & Johnson (J&J) is the brand manufacturer’s first step toward competing in the generic drug market, according to a spokeswoman for a J&J subsidiary.
Boston Scientific may not be rebounding from the multiple recalls of its blockbuster Taxus stent as quickly as company officials are claiming, according to recently released stent utilization data.
Legislation pending in California that would require pharmaceutical benefit managers (PBMs) to disclose information about their transactions with drugmakers could raise the cost of drugs, according to recent analysis by the FTC.
Drugmakers spend relatively little on R&D compared to what they spend on marketing, according to a prominent industry critic who argues that U.S. big pharma should be subject to a national pricing scheme similar to one in Canada.
Consumer group Public Citizen is calling for a federal investigation into whether four nonprofit seniors groups received $41 million from PhRMA in 2002 to improperly support candidates friendly to the pharmaceutical industry.
Antidepressant use by children and adolescents has decreased by more than 20 percent in light of FDA warnings that such medicines have the potential for exacerbating suicidal tendencies among youth, according to one pharmaceutical benefit manager (PBM).
Pointing to the European experience with parallel drug trade, a high-ranking Pfizer executive is arguing that drug importation in the U.S. can be done safely and could actually improve drugmakers’ bottom lines.
Allowing prescription drug importation could result in a drastic reduction in R&D spending by the pharmaceutical and biotechnology industries, according to a new report prepared by a public policy think tank.